Research programme: neurodegenerative disorders therapeutics - Horizon Pharma/Roche

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Horizon Pharma/Roche

Latest Information Update: 14 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Raptor Pharmaceutical Corp; Roche
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurodegenerative disorders

Most Recent Events

  • 12 Aug 2014 No development reported - Preclinical for Neurodegenerative disorders in USA (IV)
  • 30 Sep 2009 TorreyPines Therapeutics Inc has merged with Raptor Pharmaceuticals Corp to form Raptor Pharmaceutical Corp
  • 09 Jun 2009 Preclinical trials in Neurodegenerative disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top